- Mannen onder endocriene therapie (aangevraagd door onco of uro)
- Vrouwen (indien zeer lage waarden of > 50 ng/dL ter controle)
- Kinderen
| Leeftijd | Mannen | Vrouwen |
|---|---|---|
| < 7 d | 6.0-78.0 ng/dL | 6.0-78.0 ng/dL |
| 7 d-3 md | 14.0-363.0 ng/dL | <20.0 ng/dL |
| 3 md-6 md | 3.0-89.0 ng/dL | <12.0 ng/dL |
| 6 md-12 md | 3.0-12.0 ng/dL | 3.0-20.0 ng/dL |
| 12 md-4 j | 3.0-20.0 ng/dL | <18.0 ng/dL |
| 4 j-7 j | 3.0-26.0 ng/dL | <20.0 ng/dL |
| 7 j-9 j | 3.0-23.0 ng/dL | 3.0-29.0 ng/dL |
| 9 j-11 j | 2.0-57.0 ng/dL | 2.0-42.0 ng/dL |
| 11 j-13 j | 7.0-747.0 ng/dL | 6.0-64.0 ng/dL |
| 13 j-15 j | 33.0-585.0 ng/dL | 9.0-49.0 ng/dL |
| 15 j-17 j | 185.0-886.0 ng/dL | 8.0-63.0 ng/dL |
| 17 j-30 j | 11.0-59.0 ng/dL | |
| 30 j-39 j | 267.0-929.0 ng/dL | |
| 39 j-40 j | 11.0-56.0 ng/dL | |
| 40 j-49 j | 235.0-929.0 ng/dL | |
| 49 j-50 j | 5.8-47.6 ng/dL | |
| 50 j-51 j | 9.0-55.0 ng/dL | |
| 51 j-59 j | 219.0-929.0 ng/dL | |
| 59 j-69 j | 218.0-929.0 ng/dL | |
| 69 j-79 j | 218.0-926.0 ng/dL | |
| > 79 j | 157.0-913.0 ng/dL | 6.0-25.0 ng/dL |